#ATHA

@smcapstrategist.bsky.social

2 months ago

News; ( NASDAQ: #ATHA ) Athira Pharma Inc. (NASDAQ: ATHA) Records 52-Week High Thursday Morning

0 0 0 0

Small Cap Strategist

2 months ago

Most Searched, Thursday December 18, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Dec 18th - #ATHA #RZLV #WRD #TWO #TLRY #SRPT #SOC #RAMP #PTEN #ONDS #$OBE #MGNX #IQ #FCEL #FBYD #DAWN #DAVE #CAAS #ALLO #AESI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

2 months ago

Trade Alerts, Thursday December 18, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Thu Dec 18th - #MRRDF #ISSC #HQI #FCEL #EHTH #ATHA #SOC - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Stock Master

@stockmaster70.bsky.social

2 months ago

📢 Stocks Trending NOW: #MU #DJT #LULU #ACN #OXY #DVN #ASML #ATHA #ARM #MDLN

0 0 0 0

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene

2 months ago

#ATHA Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

www.stocktitan.net/news/ATHA/athira-pharma-...

0 0 0 0

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Athira Pharma (NASDAQ: ATHA) reported Q3 2025 results and a business update on November 6, 2025. The company said it is exploring strategic alternatives and engaged Cantor Fitzgerald as advisor. Athira presented Phase 1 results for ATH-1105 showing favorable safety, dose-proportional pharmacokinetics and CNS penetration in 80 healthy volunteers, supporting further development toward ALS patients.Corporate moves included a 10-for-1 reverse stock split effective September 17, 2025. Financials: $25.2M cash and investments as of September 30, 2025; $26.3M net cash used in operations for nine months ended Sept 30, 2025; Q3 net loss of $6.6M or $1.68 per share.

4 months ago

#ATHA Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ATHA/athira-pharma-...

0 0 0 0

Novel Oral ALS Drug Candidate ATH-1105 Demonstrates Favorable Safety Profile in Early Trial Athira's ATH-1105 shows positive safety results and brain penetration in Phase 1 study. This oral drug candidate offers a new approach to treating ALS. Learn more details.

7 months ago

#ATHA Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

www.stocktitan.net/news/ATHA/athira-pharma-...

0 0 0 0

Nichols

@nichols.newgrounds.com

9 months ago

Lotsa sketches

#art #digitalart #simpsons #l4d2 #xra #yakuza #atha #residentevil #spongebob #primus #ff7

10 0 0 0

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates Athira Pharma (NASDAQ: ATHA) reported Q1 2025 financial results and provided updates on its pipeline, particularly focusing on ATH-1105, its potential treatment for ALS. The company completed a Phase 1 clinical study of ATH-1105 in healthy volunteers, demonstrating favorable safety and tolerability. The full data is expected in H2 2025, with plans to begin dosing ALS patients in late 2025. Financially, Athira reported cash and investments of $36.7 million as of March 31, 2025, with a net loss of $9.1 million ($0.23 per share). The company's R&D expenses decreased to $4.3 million from $21.2 million year-over-year, while G&A expenses reduced to $5.2 million from $6.5 million. Following unsuccessful results of its previous lead candidate fosgonimeton in Alzheimer's disease, Athira is exploring strategic alternatives with Cantor Fitzgerald & Co. to maximize stockholder value.

10 months ago

#ATHA Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

www.stocktitan.net/news/ATHA/athira-pharma-...

0 0 0 0

ATHA

@akhaltekeha.bsky.social

11 months ago

Summer is near! Anyone else feeling the summer vibes this weekend?
.
.
.
Pic by @jasmins_jungle
.
.
#atha #akhaltekehorseassociation #akhalteke #goldenhorse #equestrian #horse #sᴜᴍᴍᴇʀᴠɪʙᴇs #summerlovin #horses #rarebreed

6 0 0 0

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates Athira Pharma (NASDAQ: ATHA) has completed its Phase 1 clinical study of ATH-1105 for amyotrophic lateral sclerosis (ALS) treatment. The study, involving 80 healthy volunteers, demonstrated favorable safety profiles and good tolerability, positioning the company to begin dosing ALS patients in 2025.The company reported significant financial changes, with cash positions decreasing to $51.3 million as of December 31, 2024, compared to $147.4 million in 2023. Net loss improved to $96.9 million ($2.52 per share) from $117.7 million ($3.09 per share) in 2023. R&D expenses decreased to $70.7 million from $93.8 million, while G&A expenses reduced to $26.1 million from $33.3 million.Following unsuccessful LIFT-AD Phase 2/3 trial results for fosgonimeton in Alzheimer's disease, Athira has paused its development and engaged Cantor Fitzgerald & Co. to explore strategic alternatives for maximizing stockholder value.

1 year ago

#ATHA Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

www.stocktitan.net/news/ATHA/athira-pharma-...

0 0 0 0

ATHA

@akhaltekeha.bsky.social

1 year ago

Have you kissed an Akhal Teke today?
.
.
.
#akhaltekehorseassociation #atha #akhalteke #valentine #kiss #boopthesnoot #horse #horses #equestrian #equestrianlife #horselove

1 0 0 0

ATHA

@akhaltekeha.bsky.social

1 year ago

Snow in the Netherlands! Did you get snow??
.
#atha #akhaltekehorseassociation #akhalteke #horse #snow

2 0 0 0

1 year ago

News; ( NASDAQ: #ATHA ) Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting

#StockMarket #News

1 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #ATHA ) Athira Pharma Inc. (NASDAQ: ATHA) Highlighted for Surprising Price Action

#StockMarket #News

1 0 0 0